CAR-NK在实体瘤治疗中的研究进展

Research advances of CAR-NK cell therapy in solid tumors

肿瘤免疫细胞治疗近年来备受瞩目。嵌合抗原受体T(chimeric antigen receptor engineered T-cell, CAR-T)细胞用于治疗血液系统恶性肿瘤已经颇见成效,但在实体瘤治疗方面却存在不足。由于具有不同于T细胞的非特异性杀伤肿瘤细胞的能力,CAR修饰的自然杀伤(nature killer, NK)细胞逐渐成为研究热点。目前,广泛的临床前研究证明了CAR-NK细胞疗法的安全性和有效性,尤其在实体瘤治疗方面,展现出了优于CAR-T细胞的应用前景。然而,CAR-NK细胞疗法仍存在一些局限性,需要进一步研究以期实现其临床转化。

Tumor immune cell therapy has attracted much attention in recent years.Chimeric antigen receptor engineered T-cell(CAR-T) cells have been used to treat hematological malignancies with great success, but there are shortcomings in the treatment of solid tumors.Due to their ability to kill tumor cells differently from T cells, CAR-modified nature killer(NK) cells have gradually become a research hotspot.At present, extensive preclinical studies have proved the safety and efficacy of CAR-NK cell therapy, especially in the treatment of solid tumors, showing better application prospects than CAR-T cells.However, CAR-NK cell therapy still has some limitations, and further research is needed to achieve its clinical translation.